Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $928,950.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.89, for a total transaction of $928,950.00. Following the completion of the transaction, the chief executive officer now owns 575,661 shares of the company’s stock, valued at $9,722,914.29. This trade represents a 8.72 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Saurabh Saha also recently made the following trade(s):

• On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.24, for a total value of $30,479.04.
• On Wednesday, October 23rd, Saurabh Saha sold 2,592 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.32, for a total transaction of $39,709.44.
• On Monday, October 21st, Saurabh Saha sold 22,205 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.80, for a total value of $350,839.00.
• On Friday, September 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $16.53, for a total transaction of $909,150.00.
• On Tuesday, September 10th, Saurabh Saha sold 175,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.52, for a total value of $2,891,000.00.

Centessa Pharmaceuticals Stock Down 6.3 %

Shares of NASDAQ CNTA opened at $17.04 on Friday. The company has a market capitalization of $1.93 billion, a P/E ratio of -11.14 and a beta of 1.47. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals plc has a 52-week low of $5.58 and a 52-week high of $18.74. The company’s 50 day moving average price is $16.09 and its 200-day moving average price is $12.40.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.05. Equities analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Guggenheim increased their price target on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th. Oppenheimer reaffirmed an “outperform” rating and issued a $14.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Morgan Stanley raised Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $11.00 to $26.00 in a report on Thursday, September 19th. BMO Capital Markets lifted their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a report on Monday, September 16th. Finally, Jefferies Financial Group lifted their price target on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $25.83.

Institutional Trading of Centessa Pharmaceuticals

Several large investors have recently made changes to their positions in CNTA. Mirae Asset Global Investments Co. Ltd. grew its position in Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after purchasing an additional 826 shares during the period. GAMMA Investing LLC grew its position in Centessa Pharmaceuticals by 103.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after purchasing an additional 1,509 shares in the last quarter. Quarry LP increased its position in shares of Centessa Pharmaceuticals by 47.8% during the second quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after acquiring an additional 3,108 shares during the last quarter. Sandia Investment Management LP bought a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter worth $90,000. Finally, Fred Alger Management LLC bought a new stake in Centessa Pharmaceuticals in the second quarter worth about $99,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.